Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Conditions

Subcategories:Axial SpondyloarthritisGout and Crystalline ArthritisGuidelinesMyositisOsteoarthritis and Bone DisordersOther Rheumatic ConditionsPain SyndromesPediatric ConditionsPsoriatic ArthritisRheumatoid ArthritisSjögren’s DiseaseSoft Tissue PainSystemic Lupus ErythematosusSystemic SclerosisVasculitis

Ustekinumab May Be Effective for Lupus

  |  

New research underscores the possibility that interleukin (IL) 12, IL-23 or both play roles in the immunopathology of SLE. In the study, when added to standard-of-care treatment for active SLE, ustekinumab demonstrated better efficacy than placebo and had a safety profile consistent with that of ustekinumab therapy in other diseases…

Ixekizumab Improves Outcomes of Ankylosing Spondylitis

Will Boggs, MD  |  

NEW YORK (Reuters Health)—Ixekizumab improves signs and symptoms in patients with radiographic axial spondyloarthritis (ankylosing spondylitis), according to results from the COAST-W study. “Ankylosing spondylitis is a chronic and debilitating disease, and I have a large number of patients who have failed TNF inhibitors,” says Dr. Atul Deodhar from Oregon Health and Science University, Portland….

Is More Better? Weight Loss Analysis in Older Patients with Knee OA

Arthritis Care & Research  |  

Obesity is a modifiable risk factor for many patients with knee osteoarthritis (OA), and the National Institutes of Health recommend an initial weight loss goal of 10%. But how does losing more weight affect knee OA patients? In a new study, researchers compared the outcomes of knee OA patients who lost more and less than the recommended 10% of their baseline weight, finding significant improvement in health-related quality of life and reduction in pain for patients who lost twice what’s recommended…

Genetic Discoveries Pave New Pathways to the Origins of Rheumatic Diseases

  |  

New research has provided a never-before-seen view of the genetic activity that may be used to map the polygenic nature of common rheumatic diseases. Two recent studies have employed distinct approaches to identify the non-coding gene variants, digging deep into human genetic data to uncover the mechanism of rheumatic diseases…

Mirtazapine Ineffective for Fibromyalgia

  |  

Mirtazapine has been prescribed off-label to fibromyalgia patients who have not responded to other treatments. However, a recent systemic review found no difference between mirtazapine and placebo for these patients, and any potential benefits from mirtazapine may not outweigh its potential harm, including drowsiness, weight gain and liver damage…

Gene Therapy for OA

  |  

Background & objective: One of the major challenges in the treatment of chronic joint diseases, such as osteoarthritis (OA), is the need to provide sustained bioavailability of a therapeutic agent within the joint. Systemically administered drugs cannot sufficiently reach the synovial space, and intra-articularly injected agents are cleared from the joint fluid rapidly by the…